Recent articles
Here's Why Rigel Pharmaceuticals Is Erupting This Week
The pharmaceutical stock is surging after providing preliminary results for the fourth quarter of 2019.
2 Top Renewable Energy Stocks to Buy Right Now
These two renewable energy stocks offer investors a way to own a piece of the ongoing energy transition, which will accelerate in the 2020s.
Here's Why Clovis Oncology Rose as Much as 25.6% Today
Investors might be getting a little carried away with news from the FDA.
2 Top Growth Stocks to Buy in January
Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.
2 High-Yield Stocks at Rock-Bottom Prices
These two industry leaders pay handsome dividends and aren't getting enough respect from the market, which puts them in play for income investors and value investors alike.
Here's Why Thermo Fisher Scientific Jumped 45.1% in 2019
The business grew only slightly, but the company invested in key areas to support future growth.
Here's Why Nektar Therapeutics Shares Rose as Much as 19.7% Today
The company announced a new development plan with Bristol-Myers Squibb.
Here's Why Matinas Biopharma Shares Fell as Much as 23.6% Today
The company announced the pricing of a public stock offering.
Here's Why Portola Pharmaceuticals Fell as Much as 45.4% Today
Investors ran away after the business provided preliminary full-year 2019 results.
Here's Why Mylan Fell 26.6% in 2019
It was a trying year for the generic drug manufacturer. Can a combination with Pfizer help to soothe beleaguered investors?
Here's Why Edwards Lifesciences Stock Rose 52.3% in 2019
The medical device developer kept its growth engine humming along last year. It expects double-digit growth again in 2020.
Here's Why Guardant Health Shares Rose 107.9% in 2019
As its stock chart suggests, the liquid biopsy pioneer crushed it on nearly every metric last year.
Here's Why DuPont Fell 40.5% in 2019
The stock lost value last year, but not 40.5%. The breakup of DowDuPont is reflected in the stock chart, but so, too, are sensible concerns over a major source of uncertainty.
Here's Why CRISPR Therapeutics Stock Jumped 113.2% in 2019
The gene-editing pioneer reported data from the first two patients dosed with its first drug candidate. The early results didn't disappoint.
Here's Why Clovis Oncology Stock Sank 41.9% in 2019
The pharmaceutical company's lead drug product continued to underwhelm. Just-released preliminary fourth-quarter results show much of the same.
Here's Why Bloom Energy Dropped 25.1% in 2019
The fuel cell developer had a trying year financially, but a strong third-quarter performance instilled optimism in investors.
Here's Why Solid Biosciences Fell as Much as 16.3% Today
The company announced plans to slash its head count and go all in on a single gene therapy. Is that wise or stubborn?
Here's Why Arrowhead Pharmaceuticals Stock Soared 410% in 2019
The RNAi drug developer tickled investors with promising clinical data.
Why Alnylam Pharmaceuticals Rose 57.9% in 2019
All of the share price gains came after September -- and for good reason.
2 Small-Cap Stocks With Big-Cap Potential
These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.